Sexually Dimorphic Accumulation of Persistent Organic Pollutants in Fetuses

Richelle D. Björvang1,2 and Linn Salto Mamsen3*

1Department of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, 2Division of Obstetrics and Gynecology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet and Karolinska University Hospital Huddinge, Stockholm, Sweden, 3Laboratory of Reproductive Biology, The Juliane Marie Centre for Women, Children and Reproduction, University Hospital of Copenhagen, University of Copenhagen, Copenhagen, Denmark

Living in an industrialized era, we are exposed to man-made chemicals including persistent organic pollutants (POPs). Previous studies have shown associations of POP exposure with adverse outcomes in humans, wildlife, and the environment, making it a global concern. Exposure during sensitive windows of susceptibility such as fetal development is of particular concern because of the potential increased risk of developing diseases in childhood and adulthood. However, there are limited studies on the sexual dimorphism of POP accumulation during the prenatal period. In this mini-review, we focus on differences in POP concentrations in the placenta and fetal tissues between males and females. We also show the sexually dimorphic adverse outcomes of prenatal exposure to POPs. Overall, our summary shows that males may accumulate higher concentrations of POPs in the placenta and fetal tissues compared to females, although studies are sparse and inconsistent. In addition, there are differences in adverse health outcomes associated to prenatal POP exposure according to sex. Hence, we highly urge researchers investigating the health effects of POP exposure to consider sexual dimorphism in their studies.

Keywords: human fetal exposure, persisting organic pollutants, sex differences, chemical transfer, PCB, OCP, PBDE, PFAS

INTRODUCTION

Our modern, industrialized society has developed countless improvements for everyday life. Although these developments come with many benefits, they can also cause adverse health effects in humans and wildlife. One important example is exposure to man-made industrial chemicals such as persistent organic pollutants (POPs), which is now ubiquitous in day-to-day life. POPs are halogenated organic chemicals, which means that they are carbon-based with either chlorine, fluorine or bromine attached to the carbon. Due to their structure and high stability, they are highly resistant to degradation. Their half-lives range from one to 30 years in humans (Trudel et al., 2011; Bu et al., 2015; Li et al., 2018). They are persistent, toxic and bioaccumulate in living organisms including humans. Some are volatile at certain temperatures, making them widely distributed throughout the environment, and can be found even in areas thousands of kilometers away from their sources (Stockholm Convention, 2008b).

These man-made chemicals have been found to disrupt endocrine activity and are thus named endocrine-disrupting chemicals (EDCs). Studies of humans, wildlife, multiple experimental animals, and epidemiological cohorts show associations between EDC exposure and adverse health effects,
making this a global health concern (Bergman et al., 2013). These derived effects of EDC exposure have a negative impact not only on the health and well-being of humans and wildlife but also to the economy. A recent estimate suggested that the European countries alone spend 157 billion euros a year to treat health disorders derived from EDC exposure (Trasande et al., 2015). This estimate included only three health outcomes (reproductive health, neurodevelopmental disorders, and metabolic disorders) and were based on a limited selection of EDCs (brominated flame retardants, pesticides, and phthalates and bisphenol A), implying that the true cost of EDC exposure is expected to be even larger. Therefore, EDC exposure is likely to contribute substantially to burden of disease and costs.

The primary route of exposure to POPs in humans is through ingestion, inhalation and absorption (Bergman et al., 2013; Gore et al., 2015). Further exposure occurs through placental transfer from mother to the fetus (Mamsen et al., 2017, 2019; Björvang et al., 2021), and after birth through breastfeeding (Krysiak-Balyn et al., 2010). Because POPs are found almost everywhere, exposure of the next generation starts even before conception. Studies have shown that human oocytes are extensively exposed to mixtures of these chemicals (Björvang and Damdimopoulou, 2020; Björvang et al., 2021; Lefebvre et al., 2021). Several studies have also found POPs to have a negative effect on human spermatogenesis, though the pathophysiological mechanisms are not fully elucidated (Toft et al., 2012; Sharma et al., 2020).

This mini-review focuses on a subgroup of POPs including organochlorine pesticides (OCPs), polychlorinated biphenyls (PCBs), polybrominated diphenyl ethers (PBDEs), and perfluoroalkyl substances (PFASs), which are still widely distributed in our environment. OCPs, PCBs, and PBDEs are lipophilic and deposit to adipose tissue (Mustieles and Arrebola, 2020) while PFASs are amphiphilic and predominantly bind to proteins (Forsthuber et al., 2020). The OCPs, PCBs, and PBDEs have been banned for several decades while the PFASs has just been recently regulated (Stockholm Convention, 2008a). Nonetheless, they are still present in the environment due to their high resistance to degradation as well as unintentional production as industrial by-products.

The negative impact of POPs on health is increasingly well-documented and it is becoming clear that exposure to POPs during critical windows of susceptibility such as fetal development can have long-lasting consequences for the exposed individual (Bergman et al., 2013; Gore et al., 2015). Animal studies have revealed that prenatal exposure to POPs are associated with reduced postnatal survival, low birth weight, epigenetic alterations, disrupted thyroid function, birth defects including cleft palate, anasarca, and heart disorders, and compromised fertility (Thibodeaux et al., 2003; Lau et al., 2004, 2006; Yu et al., 2009; Guo et al., 2014; Negri et al., 2017). Human prenatal exposure to POPs have been associated with reduced birth weight (Fei et al., 2007; Maisonet et al., 2012; Johnson et al., 2014; Callan et al., 2016; Lauritzen et al., 2016), though reports are inconsistent (Olsen et al., 2009; Bach et al., 2015; Yang et al., 2021). In addition, an increased risk for congenital cerebral palsy, retarded lung maturation, and thyroid dysregulation have been reported (Maervoet et al., 2007; Abdelouahab et al., 2013; Liew et al., 2014; Luo et al., 2017; Sorli et al., 2020). While studies have investigated associations between prenatal exposure and adverse health outcomes, only few studies considered potential sex-specific differences. In this mini-review, we focus on the sexual dimorphism of prenatal POP exposure.

Human Male Fetuses May Be More Exposed to POPs Than Female Fetuses

Since it is not possible to acquire fetal tissues in birth cohorts, there are only a limited number of studies with the unique opportunity to analyze the actual chemical concentrations in human fetal tissues. The available data are from fetal tissues obtained either from elective pregnancy terminations or stillbirths (Curley et al., 1969; Nishimura et al., 1977; Schecter et al., 2006; Doucet et al., 2009; Pusiol et al., 2016; Mamsen et al., 2017, 2019; Zota et al., 2018; Björvang et al., 2021). Among these nine studies, only three investigated the sexual dimorphism of POP exposure (Nishimura et al., 1977; Mamsen et al., 2019; Björvang et al., 2021) while Zota and colleagues (2018) only adjusted for fetal sex when looking into the association between fetal liver PBDEs and fetal cytochrome P450 gene expression. Nishimura et al. (1977) did not find any relationship between fetal sex and OCPs and PCBs in the fetal brain, heart, liver, kidneys, and skin. Similarly, Mamsen et al. (2019) found no association between fetal sex and PFASs in the fetal tissues including central nervous system, heart, lung, liver, and adipose tissue. On the other hand, Björvang et al. (2021) found higher concentrations of OCPs and PCBs in the male fetal brain, heart, and lung. In general, different subgroups of POPs accumulate to different fetal organs. The highest fetal PFAS concentrations were detected in liver and lung tissues, whereas the OCPs and PCBs primarily accumulated to fetal adipose tissue (Mamsen et al., 2019; Björvang et al., 2021). However, more studies are needed in relation to sexual dimorphism. Taken together, male sex may be associated with higher fetal concentrations of some POPs, though data are sparse and inconsistent (Figure 1).

Higher Levels of POPs Accumulate in Placentas With Male Fetuses Than Placentas With Female Fetuses

Prenatal exposure to chemicals is commonly estimated through surrogate matrices such as the placenta, among others. Studies have detected higher concentrations of POPs including OCPs, PBDEs, and PCBs in human placental tissues with male newborns compared to placentas with female newborns (Leonetti et al., 2016; Kim et al., 2019). Higher concentrations of OCPs and PCBs have been reported in human placentas with male fetuses in second and third trimester of pregnancy (Björvang et al., 2021) and higher placental PFASs concentrations can be detected in pregnancies with male fetuses already during first trimester (Mamsen et al., 2019), suggesting that the sex dimorphic chemical transfer is established very early in fetal life and throughout pregnancy (Figure 1).
Sexually Dimorphic Placental Development

Rodent models have demonstrated a sexually dimorphic development of the placenta, with a slower placental development and more protective adaptive responses to stressful environments in females compared to males (Kalisch-Smith et al., 2017; Saoi et al., 2020). Transcriptome analysis of human first- and second trimester placentas confirm different expression patterns between the sexes (Gonzalez et al., 2018; Braun et al., 2021), which can also be detected in term placentas (Sood et al., 2006). When the intrauterine environment is disturbed in rodents and humans, placentas with male fetuses consume more energy to accelerate its own growth as well as the fetus’, accelerating epigenetic aging at the expense of adaptability and plasticity (Tekola-Ayele et al., 2019; Yu et al., 2021). In contrast, placentas with female fetuses respond to disturbances with protective mechanisms such as slowing down growth and metabolism to ensure fetal survival (Miller et al., 2020; Phuthong et al., 2020; Saoi et al., 2020; Weinheimer et al., 2020). These different growth strategies in response to disturbances may place male fetuses at a greater risk when exposed to POPs or other disturbing pollutants. In addition, sexually dimorphic placental function has also been reported in humans, which may facilitate a skewed accumulation of chemicals between the sexes (Rosenfeld, 2015). Pregnancies with female fetuses have higher placental vascular resistance compared to that of pregnancies with male fetuses (Widnes et al., 2017), which may affect the blood flow to the fetus and thereby, support a different chemical transfer between sexes. Moreover, epigenetic patterns in the placenta differed between the sexes (Martin et al., 2017), which may also explain the diverging susceptibility to chemicals and health outcomes. For example, maternal exposure to OCPs, PCBs, and PBDEs have been associated with sex-dimorphic epigenetic changes in placental genes involved in the placental transfer of thyroid hormones (Kim et al., 2019). The human fetal metabolizing machinery has also been evaluated in relation to maternal use of over-the-counter analgesics and found that some enzymes involved in pharmacokinetic and pharmacodynamic pathways are significantly affected by fetal sex and gestational age (Zafeiri and Fowler, 2021). Taken together, these reports implies that the higher accumulation of chemicals observed in male fetuses than female fetuses may be caused by different placental development, function, epigenetics, and metabolism between the sexes.

Adverse Outcomes Differ According to Sex

Sexually dimorphic adverse outcomes of PFAS exposure have been described in rodents, where prenatal exposure to PFOA significantly affected fetal growth and development in males but to a much lesser extent in females (Nakayama et al., 2005; Negri et al., 2017). The higher sensitivity of male fetuses may be related to a less efficient elimination of PFOA in males, which have been observed in rodents (Vanden Heuvel et al., 1991). In humans, in utero exposure to POPs has been associated with reduced birth weight in some studies, although results are inconsistent (Olsen et al., 2009; Tan et al., 2009; Govarts et al., 2012; Bach et al., 2015; Casas et al., 2016).
et al., 2015; Lauritzen et al., 2017). One study found the reduced birth weight to be more pronounced in male offspring (Lauritzen et al., 2017) while another study found the correlation only in female offspring (Washino et al., 2009). On the other hand, Covarts and colleagues (2012) did not find any sex-specific effects.

Prenatal exposure to some OCPs has been associated with higher body mass index (BMI) in girls up to two years after birth (Mendez et al., 2011; Valvi et al., 2014; Coker et al., 2018; Yang et al., 2021), implying that prenatal exposure may cause physiological changes predisposing to later weight gain. In addition, in utero exposure to PFAS has been positively associated with BMI in females at 20 years of age (Halldorsson et al., 2012). Exposure to EDCs has been associated with an increased obesity risk, which may be due to disturbance in the regulation of endocrine hormones or the hypothalamic-pituitary-adrenal axis that regulate homeostatic mechanisms important to weight control (Grün and Blumberg, 2009; Tang-Péronard et al., 2011).

Prenatal exposure to OCPs and PBDEs have been associated with reduced maternal supply of thyroid hormones to the fetus, which may affect the thyroid hormone balance in newborns (Maervoet et al., 2007; Abdelouahab et al., 2013; Luo et al., 2017; Krönke et al., 2021). Prenatal exposure to PCBs were positively associated with the level of thyroid hormones in female children 6 months after birth, while OCPs were negatively associated with the level of thyroid hormones of male children 1 year after birth (Krönke et al., 2021).

CONCLUSION

POPs accumulate at higher concentrations in human male fetuses and their placentas than in female fetuses and their placentas. This may be caused by a sexually dimorphic genetic and epigenetic regulation, placental resistance, and protective strategies to external stress. The sexual dimorphic fetal accumulation may be caused by differences in placental transfer and by differences in fetal pharmacokinetic, and endocrine milieu. Prenatal exposure to POPs has been associated with adverse health outcomes, though sex-specific effects are sparse and inconsistent. Most exposure studies do not monitor potential sex dimorphic outcomes, which leave us with a research gap that merits consideration and highlight the need for more studies including fetal sex as a potential covariate.

AUTHOR CONTRIBUTIONS

RB and LM searched, synthesized and interpreted the literature and drafted the paper. Both authors approved the last version of the manuscript.

FUNDING

This work was supported by the EU interregional project ReproUnion 2.0 (LM), Aase and Eijnar Danielsens Fond (LM), and Birgitta and Carl-Axel Rydbeck’s Research grant (RB).

REFERENCES

Abdelouahab, N., Langlois, M.-F., Lavoie, L., Corbin, F., Pasquier, J.-C., and Takser, L. (2013). Maternal and Cord-Blood Thyroid Hormone Levels and Exposure to Polybrominated Diphenyl Ethers and Polychlorinated Biphenyls during Early Pregnancy. Am. J. Epidemiol. 178, 701–713. doi:10.1093/aje/kwt141

Bach, C. C., Bech, B. H., Brix, N., Noth, E. A., Bonde, J. P. E., and Henriksen, T. B. (2015). Perfluorooalkyl and Polyfluoroalkyl Substances and Human Fetal Growth: A Systematic Review. Crit. Rev. Toxicol. 45, 53–67. doi:10.3109/10408444.2014.952400

Bergman, Å., Heindel, J., Jobling, S., Kidd, K., and Zoeller, R. T. (2012). State-of-the-science of Endocrine Disrupting Chemicals, 2012. Toxicol. Lett. 211, S3. doi:10.1016/j.toxlet.2012.03.020

Björvang, R. D., and Damdimopoulou, P. (2020). Persistent Environmental Endocrine-Disturbing Chemicals in Ovarian Follicular Fluid and In Vitro Fertilization Treatment Outcome in Women. Upsala J. Med. Sci. Med. Sci. 125, 85–94. doi:10.1080/03009734.2020.1727073

Björvang, R. D., Vinners, M.-T., Papadogiannakis, N., Gidlöf, S., Mamsen, L. S., Mucs, D., et al. (2021). Mixtures of Persistent Organic Pollutants Are Found in Vital Organs of Late Gestation Human Fetuses. Chemosphere 283, 131125. doi:10.1016/j.chemosphere.2021.131125

Braun, A. E., Munch, K. L., Robinson, B. G., Wang, A., Palmer, T. D., and Winn, V. D. (2021). Examining Sex Differences in the Human Placental Transcriptome during the First Fetal Androgen Peak. Reprod. Sci. 28, 801–818. doi:10.1007/s12655-020-00355-8

Bu, Q., MacLeod, M., Wong, F., Toms, L. M. L., Mueller, J. F., and Yu, G. (2015). Historical Intake and Elimination of Polychlorinated Biphenyls and Organochlorine Pesticides by the Australian Population Reconstructed from Biomonitoring Data. Environ. Int. 74, 82–88. doi:10.1016/j.envint.2014.09.014

Callan, A. C., Hinwood, A. L., Heyworth, J., Phil, D. T., and Olland, J. O. (2016). Sex Specific Influence on the Relationship between Maternal Exposures to Persistent Chemicals and Birth Outcomes. Int. J. Hyg. Environ. Health 219, 734–741. doi:10.1016/j.ijheh.2016.09.018

Casas, M., Nieuwenhuijsen, M., Martinez, D., Ballester, F., Basagaña, X., Basterrechea, M., et al. (2015). Prenatal Exposure to PCB-153, P,p’-DDE and Birth Outcomes in 9000 Mother-Child Pairs: Exposure-Response Relationship and Effect Modifiers. Environ. Int. 74, 23–31. doi:10.1016/j.envint.2014.09.013

Coker, E., Chevrier, J., Rauch, S., Bradman, A., Obida, M., Craise, M., et al. (2018). Association between Prenatal Exposure to Multiple Insecticides and Child Body Weight and Body Composition in the VHEMBE South African Birth Cohort. Environ. Int. 113, 122–132. doi:10.1016/j.envint.2018.01.016

Curley, A., Copeland, M. F., and Kimbrough, R. D. (1969). Chlorinated Hydrocarbon Insecticides in Organs of Stillborn and Blood of Newborn Babies. Archives Environ. Health Int. J. 19, 628–632. doi:10.1007/00039896.1969.1066991

Doucet, J., Tague, B., Arnold, D. L., Cooke, G. M., Hayward, S., and Goodyer, C. G. (2009). Persistent Organic Pollutant Residues in Human Fetal Liver and Placenta from Greater Montreal, Quebec: A Longitudinal Study from 1998 through 2006. Environ. Health Perspect. 117, 605–610. doi:10.1289/ehp.0800205

Fei, C., McLaughlin, J. K., Tarone, R. E., and Olsen, J. (2007). Perfluorinated Chemicals and Fetal Growth: A Study within the Danish National Birth Cohort. Environ. Health Perspect. 115, 1677–1682. doi:10.1289/ehp.10506

Forsthüber, M., Kaiser, A. M., Granitzer, S., Haski, L., Hengstschläger, M., Stangl, H., et al. (2020). Albumin Is the Major Carrier Protein for PFOS, PFOA, PFHxS, PFNA and PFDA in Human Plasma. Environ. Int. 137, 105324. doi:10.1016/j.envint.2019.105324
Pusiol, T., Lavezzi, A., Matturri, L., Termopoli, V., Cappiello, A., Piscioli, F., et al. (2016). Impact Assessment of Endocrine Disruptors on Sudden Intrauterine and Infant Death Syndromes. *Eur. J. Forensic Sci.* 3, 8. doi:10.5455/ejfs.197968

Rosenfeld, C. S. (2015). Sex-specific Placental Responses in Fetal Development. *Endocrinology* 156, 3422–3434. doi:10.1210/endo.2015-1227

Saoi, M., Kennedy, K. M., Gohir, W., Sloboda, D. M., and Britz-McKibbin, P. (2020). Placental Metabolomics for Assessment of Sex-specific Differences in Fetal Development during Normal Gestation. *Sci. Rep.* 10, 66222. doi:10.1038/S41598-020-66222-3

Schechter, A., Johnson-Welch, S., Tung, K. C., Harris, T. R., Päpke, O., and Rosen, R. (2006). Polybrominated Diphenyl Ether (PBDE) Levels in Livers of U.S. Human Fetuses and Newborns. *J. Toxicol. Environ. Health, Part A* 70, 1–6. doi:10.1080/15287390600748369

Sharma, A., Mollier, J., Brocklesby, R. W. K., Caves, C., Jayasena, C. N., and Rosenfeld, C. S. (2015). Sex-specific Effects of Postnatal Exposure to Per- and Polyfluorinated Compounds on Fetal Development. *Placenta* 36, 631–637. doi:10.1016/j.placenta.2014.11.011

Trudel, D., Scheringer, M., Von Goetz, N., and Hungerbühler, K. (2011). Total Consumer Exposure to Polybrominated Diphenyl Ethers in North America and Europe. *Environ. Sci. Technol.* 45, 2391–2397. doi:10.1021/es1035046

Valdés, D., Menéndez, M. A., García-Esteban, R., Ballester, F., Barluzer, J., Goñi, F., et al. (2014). Prenatal Exposure to Persistent Organic Pollutants and Rapid Weight Gain and Overweight in Infancy. *Obesity* 22, 488–496. doi:10.1002/oby.20603

Washino, N., Saijo, Y., Sasaki, S., Kato, S., Ban, S., Konishi, K., et al. (2009). Correlations between Prenatal Exposure to Perfluorinated Chemicals and Reduced Fetal Growth. *Environ. Health Perspect.* 117, 660–667. doi:10.1289/ EHP.11681

Weinheimer, C., Wang, H., Comstock, J. M., Singh, P., Wang, Z., Locklear, B. A., et al. (2020). Maternal Tobacco Smoke Exposure Causes Sex-Divergent Changes in Placental Lipid Metabolism in the Rat. *Repro. Sci.* 27, 631–643. doi:10.1046/j.1038-7205.2007.00065-W

Yang, C., Fang, J., Sun, X., Zhang, W., Li, J., Chen, X., et al. (2021). Prenatal Exposure to Organochlorine Pesticides and Infant Growth: A Longitudinal Study. *Environ. Int.* 148, 106374. doi:10.1016/j.envint.2020.106374

Yu, P., Chen, Y., Ge, C., and Wang, H. (2021). Sexual Dimorphism in Placental Development and its Contribution to Health and Diseases. *Crit. Rev. Toxicol.* 51, 555–570. doi:10.1080/10408444.2021.1977237/FORMAT/EPU

Yu, W.-G., Liu, W., Jin, Y.-H., Liu, X.-H., Wang, F.-Q., Liu, L., et al. (2009). Prenatal and Postnatal Impact of Perfluorooctane Sulfonate (PFOS) on Rat Development: a Cross-Foster Study on Chemical Burden and Thyroid Hormone System. *Environ. Sci. Technol.* 43, 8416–8422. doi:10.1021/es901602d

Zafeiri, A., and Fowler, P. A. (2021). Expression Patterns of Analgesic Metabolising Enzymes in Perfluorinated Chemicals and Male Reproductive Health. *Reprod. Med. Biol.* 19, 243–253. doi:10.1002/rmb2.12326

Zotin, A. G., Martsin, I. A., and Shevratkov, V. A. (1991). Distribution and Reproduction is permitted which does not comply with these terms.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2023 Björvang and Mamsen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.